Viatris Inc. (NASDAQ: VTRS) receives approval from China’s NMPA for Yupelri inhalation solution for COPD treatment, triggering a $7.5M payment to Theravance BioPharma. Yupelri is the first nebulized LAMA approved in China for COPD. VTRS operates in 4 segments, while TBPH develops and commercializes medicines in the US.

Read more at Yahoo Finance: Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma